Cargando…

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY

Detalles Bibliográficos
Autores principales:	Gregory, G., Timmerman, J., Lavie, D., Borchmann, P., Herrera, A. F., Minuk, L., Vucinic, V., Armand, P., Avigdor, A., Gasiorowski, R., Herishanu, Y., Keane, C., Kuruvilla, J., Palcza, J., Pillai, P., Marinello, P., Johnson, N. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428990/ http://dx.doi.org/10.1097/01.HS9.0000847212.00073.29

Ejemplares similares

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
por: Borchmann, Peter, et al.
Publicado: (2022)

P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
por: Johnson, Nathalie, et al.
Publicado: (2023)

P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY
por: Herrera, A. F., et al.
Publicado: (2022)

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
por: Timmerman, John, et al.
Publicado: (2022)

P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT
por: Timmerman, John, et al.
Publicado: (2023)

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
por: Garralda, E., et al.
Publicado: (2022)

P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA
por: Armand, Philippe, et al.
Publicado: (2023)

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
por: Kuruvilla, J., et al.
Publicado: (2022)

1086 CORONAVIRUS-LIKE PARTICLES AND NEONATAL GASTROINTES-TINAL DISEASE
por: Vaucher, Yvonne E, et al.
Publicado: (1981)

1086. Antimicrobial Stewardship: From Bedside to Man’s Best Friend
por: Reed, Erica E, et al.
Publicado: (2019)

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
por: Ribrag, Vincent, et al.
Publicado: (2015)

1086. COVID-19 in a Comprehensive Cancer Center: 2020-2022
por: Mulanovich, Patricia, et al.
Publicado: (2022)

Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
por: Sasson, S. C., et al.
Publicado: (2021)

T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity
por: Cemerski, Saso, et al.
Publicado: (2015)

1086. Impact of Systematic Thoraco-Abdomino-Pelvic CT Scan on the Diagnosis of Infective Endocarditis
por: Lecomte, Raphaël, et al.
Publicado: (2018)

Draft Genome Sequence of the Carboxydotrophic Alphaproteobacterium Aminobacter carboxidus Type Strain DSM 1086
por: Turrini, Paolo, et al.
Publicado: (2020)

Pembrolizumab in relapsed or refractory Richter syndrome
por: Armand, Philippe, et al.
Publicado: (2020)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Canine parvovirus induces G1/S cell cycle arrest that involves EGFR Tyr1086 phosphorylation
por: Dai, Xiaofeng, et al.
Publicado: (2020)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
por: Ott, P. A., et al.
Publicado: (2017)

Mechanisims of asthma and allergic disease – 1086. Bacteria-derived extracellular vesicles as an important causative agent for asthma and COPD
por: Jee, Young-Koo, et al.
Publicado: (2013)

1086. Epidemiology, Risk Factors, and Effect of Antifungal Prophylaxis on Early Invasive Fungal Infection in Heart Transplant Recipients
por: Yetmar, Zachary A, et al.
Publicado: (2020)

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C
por: Fouda, G, et al.
Publicado: (2012)

Pembrolizumab-Induced Anti-GBM Glomerulonephritis: A Case Report
por: El Yamani, Nidal, et al.
Publicado: (2023)

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
por: Huuhtanen, Jani, et al.
Publicado: (2023)

Perceived impact of the menstrual cycle and hormonal contraceptives on physical exercise and performance in 1,086 athletes from 57 sports
por: Ekenros, Linda, et al.
Publicado: (2022)

Offered Support and Knowledge about the Menstrual Cycle in the Athletic Community: A Cross-Sectional Study of 1086 Female Athletes
por: von Rosen, Philip, et al.
Publicado: (2022)

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021)

Mo1086: MENTAL HEALTH IN IBD DURING THE COVID-19 PANDEMIC: ACCESS TO MENTAL HEALTH CARE AND EXPOSURE TO PANDEMIC NEWS
por: Shaffer, Seth R., et al.
Publicado: (2022)

On the lag phase in amyloid fibril formation
por: Arosio, Paolo, et al.
Publicado: (2015)

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures
por: Gestermann, Nicolas, et al.
Publicado: (2020)

Non‐parallel anti‐tumour effects of pembrolizumab: a case of cardial tamponade
por: Tachihara, Motoko, et al.
Publicado: (2019)

Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy
por: Onda, Asako, et al.
Publicado: (2019)

WCN23-1086 ACUTE KIDNEY INJURY AFTER COVID 19 INFECTION IN CHRONIC KIDNEY DISEASE PATIENTS OF BANGLADESH: RETROSPECTIVE STUDY
por: NOBI, F., et al.
Publicado: (2023)

SG-APSIC1086: Case series: Examining healthcare-associated infection cases caused by Candida auris at Cho Ray Hospital, Vietnam
por: Hong, Thoa Vo Thi, et al.
Publicado: (2023)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
por: Schöffski, Patrick, et al.
Publicado: (2022)

Pre-Clinical Development of a Recombinant, Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C
por: Alexander, Jeff, et al.
Publicado: (2013)

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
por: Atkinson, Victoria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_logkgdobgj0a1il752nfdrop44